Acuitas Therapeutics

Ying Tam, chief scientific officer at Vancouver-based lipid nanoparticle maker Acuitas Therapeutics, joined In Vivo to discuss the company’s pivotal role in delivering the first personalized CRISPR

Verve Therapeutics, Inc. has paused enrollment in its Phase Ib Heart-1 trial of gene-edited cholesterol medicine VERVE-101 after a patient experienced liver enzyme elevations and low platelet counts.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. PhoreMost To Deploy SITESEEKER Platform